Protagonist Therapeutics, Inc.
US ˙ NasdaqGM ˙ US74366E1029

SecurityPTGX / Protagonist Therapeutics, Inc.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Ownership 0.70%
Citadel Advisors Llc ownership in PTGX / Protagonist Therapeutics, Inc.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (PTGX) in the form of stock options. The firm currently holds call options representing 48,800 of underlying shares valued at $5,143,520 USD and put options representing 3,700 of underlying shares valued at $389,980 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2024-02-14 2024-02-14 13G/A 0.70 -87.27
2023-01-03 2023-01-03 13G 5.50

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

PTGX / Protagonist Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,551,900 425,213 37.74 163,570 66.22 0.0233
2026-02-17 2025-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,126,687 888,806 373.63 98,405 522.73 0.0131
2025-11-14 2025-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 237,881 210,680 774.53 15,802 951.36 0.0024
2025-08-14 2025-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 27,201 -126,866 -82.34 1,503 -79.83 0.0003
2025-05-15 2025-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 154,067 -10,079 -6.14 7,451 17.58 0.0014
2025-02-14 2024-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 164,146 159,116 3,163.34 6,336 2,703.54 0.0011
2024-11-14 2024-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 5,030 5,030 226 0.0000
2024-08-14 2024-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 0 -45,616 -100.00 0 -100.00
2024-05-15 2024-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 45,616 -2,248 -4.70 1,320 20.24 0.0003
2024-02-14 2023-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 47,864 -2,932 -5.77 1,098 29.52 0.0002
2023-11-14 2023-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 50,796 -498,198 -90.75 847 -94.41 0.0002
2023-08-14 2023-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 548,994 -615,686 -52.86 15,163 -43.39 0.0031
2023-05-15 2023-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,164,680 -1,190,634 -50.55 26,788 4.25 0.0059
2023-02-14 2022-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 2,355,314 1,488,927 171.85 25,696 251.81 0.0060
2022-11-14 2022-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 866,387 792,258 1,068.76 7,304 1,146.42 0.0017
2022-08-15 2022-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 74,129 -112,695 -60.32 586 -86.75 0.0002
2022-05-16 2022-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 186,824 151,276 425.55 4,424 263.82 0.0009
2022-02-14 2021-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 35,548 -83,156 -70.05 1,216 -42.21 0.0002
2021-11-15 2021-09-30 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 118,704 -284,504 -70.56 2,104 -88.37 0.0004
2021-08-16 2021-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 403,208 204,990 103.42 18,096 252.54 0.0041
2021-05-21 2021-03-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 198,218 -142,604 -41.84 5,133 -25.29 0.0013
2021-05-17 2021-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 198,218 -142,604 5,133 0.0013
2021-02-16 2020-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 340,822 340,822 71.94 6,871 33.86 0.0018
2020-08-14 2020-06-30 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 0 -469,212 -100.00 0 -100.00
2020-05-15 2020-03-31 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 469,212 10,119 2.20 3,313 2.38 0.0015
2020-02-14 2019-12-31 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 459,093 42,838 10.29 3,236 -35.27 0.0014
2019-11-14 2019-09-30 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 416,255 6,408 1.56 4,999 0.73 0.0024
2019-08-14 2019-06-30 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 409,847 46,120 12.68 4,963 8.55 0.0023
2019-05-15 2019-03-31 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 363,727 328,965 946.34 4,572 1,853.85 0.0023
2019-02-14 2018-12-31 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 34,762 -995 -2.78 234 -36.41 0.0001
2018-11-13 2018-09-30 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 35,757 -95,644 -72.79 368 -58.32 0.0002
2018-08-14 2018-06-30 13F/A-1 PROTAGONIST THERAPEUTICS Cmn 74366E102 131,401 82,204 167.09 883 108.75 0.0004
2018-08-10 2018-06-30 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 131,401 82,204 883
2018-05-14 2018-03-31 13F/A-1 PROTAGONIST THERAPEUTICS Cmn 74366E102 49,197 49,197 423 0.0002
2018-05-11 2018-03-31 13F PROTAGONIST THERAPEUTICS Cmn 74366E102 49,197 423 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F PROTAGONIST THERAPEUTICS COM Call 48,800 -45.05 5,144 -33.68 n/a n/a n/a
2026-02-17 2025-12-31 13F PROTAGONIST THERAPEUTICS COM Call 88,800 252.38 7,756 363.26 n/a n/a n/a
2025-11-14 2025-09-30 13F PROTAGONIST THERAPEUTICS COM Call 25,200 111.76 1,674 154.79 n/a n/a n/a
2025-08-14 2025-06-30 13F PROTAGONIST THERAPEUTICS COM Call 11,900 -76.76 658 -73.47 n/a n/a n/a
2025-05-15 2025-03-31 13F PROTAGONIST THERAPEUTICS COM Call 51,200 481.82 2,476 630.38 n/a n/a n/a
2025-02-14 2024-12-31 13F PROTAGONIST THERAPEUTICS COM Call 8,800 29.41 340 10.78 n/a n/a n/a
2024-11-14 2024-09-30 13F PROTAGONIST THERAPEUTICS COM Call 6,800 -8.11 306 19.53 n/a n/a n/a
2024-08-14 2024-06-30 13F PROTAGONIST THERAPEUTICS COM Call 7,400 -32.11 256 -18.73 n/a n/a n/a
2024-05-15 2024-03-31 13F PROTAGONIST THERAPEUTICS COM Call 10,900 -96.82 315 -95.99 n/a n/a n/a
2024-02-14 2023-12-31 13F PROTAGONIST THERAPEUTICS COM Call 342,600 3.35 7,856 42.07 n/a n/a n/a
2023-11-14 2023-09-30 13F PROTAGONIST THERAPEUTICS COM Call 331,500 -4.85 5,529 -42.54 n/a n/a n/a
2023-08-14 2023-06-30 13F PROTAGONIST THERAPEUTICS COM Call 348,400 -12.79 9,623 4.72 n/a n/a n/a
2023-05-15 2023-03-31 13F PROTAGONIST THERAPEUTICS COM Call 399,500 21.98 9,188 157.15 n/a n/a n/a
2023-02-14 2022-12-31 13F PROTAGONIST THERAPEUTICS COM Call 327,500 -3.05 3,573 25.46 n/a n/a n/a
2022-11-14 2022-09-30 13F PROTAGONIST THERAPEUTICS COM Call 337,800 -37.71 2,848 -33.61 n/a n/a n/a
2022-08-15 2022-06-30 13F PROTAGONIST THERAPEUTICS COM Call 542,300 334.88 4,290 45.28 n/a n/a n/a
2022-05-16 2022-03-31 13F PROTAGONIST THERAPEUTICS COM Call 124,700 78.91 2,953 23.87 n/a n/a n/a
2022-02-14 2021-12-31 13F PROTAGONIST THERAPEUTICS COM Call 69,700 -18.48 2,384 57.36 n/a n/a n/a
2021-11-15 2021-09-30 13F PROTAGONIST THERAPEUTICS Cmn Call 85,500 515.11 1,515 142.79 n/a n/a n/a
2021-08-16 2021-06-30 13F PROTAGONIST THERAPEUTICS COM Call 13,900 39.00 624 140.93 n/a n/a n/a
2021-05-21 2021-03-31 13F/A PROTAGONIST THERAPEUTICS COM Call 10,000 259 n/a n/a n/a
2021-05-17 2021-03-31 13F PROTAGONIST THERAPEUTICS COM Call 10,000 259 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F PROTAGONIST THERAPEUTICS COM Put 3,700 -42.19 390 -30.29 n/a n/a n/a
2026-02-17 2025-12-31 13F PROTAGONIST THERAPEUTICS COM Put 6,400 3.23 559 35.77 n/a n/a n/a
2025-11-14 2025-09-30 13F PROTAGONIST THERAPEUTICS COM Put 6,200 -66.67 412 -60.02 n/a n/a n/a
2025-08-14 2025-06-30 13F PROTAGONIST THERAPEUTICS COM Put 18,600 -48.48 1,028 -41.09 n/a n/a n/a
2025-05-15 2025-03-31 13F PROTAGONIST THERAPEUTICS COM Put 36,100 28.47 1,746 60.98 n/a n/a n/a
2025-02-14 2024-12-31 13F PROTAGONIST THERAPEUTICS COM Put 28,100 138.14 1,085 104.14 n/a n/a n/a
2024-11-14 2024-09-30 13F PROTAGONIST THERAPEUTICS COM Put 11,800 55.26 531 101.90 n/a n/a n/a
2024-08-14 2024-06-30 13F PROTAGONIST THERAPEUTICS COM Put 7,600 -47.22 263 -36.78 n/a n/a n/a
2024-05-15 2024-03-31 13F PROTAGONIST THERAPEUTICS COM Put 14,400 -73.82 417 -67.01 n/a n/a n/a
2024-02-14 2023-12-31 13F PROTAGONIST THERAPEUTICS COM Put 55,000 124.49 1,261 209.07 n/a n/a n/a
2023-11-14 2023-09-30 13F PROTAGONIST THERAPEUTICS COM Put 24,500 -68.35 409 -80.91 n/a n/a n/a
2023-08-14 2023-06-30 13F PROTAGONIST THERAPEUTICS COM Put 77,400 -5.95 2,138 12.95 n/a n/a n/a
2023-05-15 2023-03-31 13F PROTAGONIST THERAPEUTICS COM Put 82,300 233.20 1,893 603.35 n/a n/a n/a
2023-02-14 2022-12-31 13F PROTAGONIST THERAPEUTICS COM Put 24,700 269 n/a n/a n/a
2022-11-14 2022-09-30 13F PROTAGONIST THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-08-15 2022-06-30 13F PROTAGONIST THERAPEUTICS COM Put 40,300 -18.59 319 -72.78 n/a n/a n/a
2022-05-16 2022-03-31 13F PROTAGONIST THERAPEUTICS COM Put 49,500 18.71 1,172 -17.81 n/a n/a n/a
2022-02-14 2021-12-31 13F PROTAGONIST THERAPEUTICS COM Put 41,700 -81.32 1,426 -63.94 n/a n/a n/a
2021-11-15 2021-09-30 13F PROTAGONIST THERAPEUTICS Cmn Put 223,200 1,700.00 3,955 610.05 n/a n/a n/a
2021-08-16 2021-06-30 13F PROTAGONIST THERAPEUTICS COM Put 12,400 557 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.